Comparative Performance of Line Probe Assay (Version 2) and Xpert MTB/RIF Assay for Early Diagnosis of Rifampicin-Resistant Pulmonary Tuberculosis

Background The emergence of drug-resistant tuberculosis (TB), is a major menace to cast off TB worldwide. Line probe assay (LPA; GenoType MTBDRplus ver. 2) and Xpert MTB/RIF assays are two rapid molecular TB detection/diagnostic tests. To compare the performance of LPA and Xpert MTB/RIF assay for ea...

Full description

Bibliographic Details
Main Authors: Raj Narayan Yadav, Binit Kumar Singh, Rohini Sharma, Jigyasa Chaubey, Sanjeev Sinha, Pankaj Jorwal
Format: Article
Language:English
Published: The Korean Academy of Tuberculosis and Respiratory Diseases 2021-07-01
Series:Tuberculosis and Respiratory Diseases
Subjects:
Online Access:http://e-trd.org/upload/pdf/trd-2020-0171.pdf
id doaj-8b38b4141bea4e5e8a7ff241ac2ed53e
record_format Article
spelling doaj-8b38b4141bea4e5e8a7ff241ac2ed53e2021-07-02T05:40:29ZengThe Korean Academy of Tuberculosis and Respiratory DiseasesTuberculosis and Respiratory Diseases1738-35362005-61842021-07-0184323724410.4046/trd.2020.01714565Comparative Performance of Line Probe Assay (Version 2) and Xpert MTB/RIF Assay for Early Diagnosis of Rifampicin-Resistant Pulmonary TuberculosisRaj Narayan YadavBinit Kumar SinghRohini SharmaJigyasa ChaubeySanjeev SinhaPankaj JorwalBackground The emergence of drug-resistant tuberculosis (TB), is a major menace to cast off TB worldwide. Line probe assay (LPA; GenoType MTBDRplus ver. 2) and Xpert MTB/RIF assays are two rapid molecular TB detection/diagnostic tests. To compare the performance of LPA and Xpert MTB/RIF assay for early diagnosis of rifampicin-resistant (RR) TB in acid-fast bacillus (AFB) smear-positive and negative sputum samples. Methods A total 576 presumptive AFB patients were selected and subjected to AFB microscopy, Xpert MTB/RIF assay and recent version of LPA (GenoType MTBDRplus assay version 2) tests directly on sputum samples. Results were compared with phenotypic culture and drug susceptibility testing (DST). DNA sequencing was performed with rpoB gene for samples with discordant rifampicin susceptibility results. Results Among culture-positive samples, Xpert MTB/RIF assay detected Mycobacterium tuberculosis (Mtb ) in 97.3% (364/374) of AFB smear-positive samples and 76.5% (13/17) among smear-negative samples, and the corresponding values for LPA test (valid results with Mtb control band) were 97.9% (366/374) and 58.8% (10/17), respectively. For detection of RR among Mtb positive molecular results, the sensitivity of Xpert MTB/RIF assay and LPA (after resolving discordant phenotypic DST results with DNA sequencing) were found to be 96% and 99%, respectively. Whereas, specificity of both test for detecting RR were found to be 99%. Conclusion We conclude that although Xpert MTB/RIF assay is comparatively superior to LPA in detecting Mtb among AFB smear-negative pulmonary TB. However, both tests are equally efficient in early diagnosis of AFB smear-positive presumptive RR-TB patients.http://e-trd.org/upload/pdf/trd-2020-0171.pdfmultidrug-resistant tuberculosis complexnontuberculous mycobacteriamutation
collection DOAJ
language English
format Article
sources DOAJ
author Raj Narayan Yadav
Binit Kumar Singh
Rohini Sharma
Jigyasa Chaubey
Sanjeev Sinha
Pankaj Jorwal
spellingShingle Raj Narayan Yadav
Binit Kumar Singh
Rohini Sharma
Jigyasa Chaubey
Sanjeev Sinha
Pankaj Jorwal
Comparative Performance of Line Probe Assay (Version 2) and Xpert MTB/RIF Assay for Early Diagnosis of Rifampicin-Resistant Pulmonary Tuberculosis
Tuberculosis and Respiratory Diseases
multidrug-resistant tuberculosis
complex
nontuberculous mycobacteria
mutation
author_facet Raj Narayan Yadav
Binit Kumar Singh
Rohini Sharma
Jigyasa Chaubey
Sanjeev Sinha
Pankaj Jorwal
author_sort Raj Narayan Yadav
title Comparative Performance of Line Probe Assay (Version 2) and Xpert MTB/RIF Assay for Early Diagnosis of Rifampicin-Resistant Pulmonary Tuberculosis
title_short Comparative Performance of Line Probe Assay (Version 2) and Xpert MTB/RIF Assay for Early Diagnosis of Rifampicin-Resistant Pulmonary Tuberculosis
title_full Comparative Performance of Line Probe Assay (Version 2) and Xpert MTB/RIF Assay for Early Diagnosis of Rifampicin-Resistant Pulmonary Tuberculosis
title_fullStr Comparative Performance of Line Probe Assay (Version 2) and Xpert MTB/RIF Assay for Early Diagnosis of Rifampicin-Resistant Pulmonary Tuberculosis
title_full_unstemmed Comparative Performance of Line Probe Assay (Version 2) and Xpert MTB/RIF Assay for Early Diagnosis of Rifampicin-Resistant Pulmonary Tuberculosis
title_sort comparative performance of line probe assay (version 2) and xpert mtb/rif assay for early diagnosis of rifampicin-resistant pulmonary tuberculosis
publisher The Korean Academy of Tuberculosis and Respiratory Diseases
series Tuberculosis and Respiratory Diseases
issn 1738-3536
2005-6184
publishDate 2021-07-01
description Background The emergence of drug-resistant tuberculosis (TB), is a major menace to cast off TB worldwide. Line probe assay (LPA; GenoType MTBDRplus ver. 2) and Xpert MTB/RIF assays are two rapid molecular TB detection/diagnostic tests. To compare the performance of LPA and Xpert MTB/RIF assay for early diagnosis of rifampicin-resistant (RR) TB in acid-fast bacillus (AFB) smear-positive and negative sputum samples. Methods A total 576 presumptive AFB patients were selected and subjected to AFB microscopy, Xpert MTB/RIF assay and recent version of LPA (GenoType MTBDRplus assay version 2) tests directly on sputum samples. Results were compared with phenotypic culture and drug susceptibility testing (DST). DNA sequencing was performed with rpoB gene for samples with discordant rifampicin susceptibility results. Results Among culture-positive samples, Xpert MTB/RIF assay detected Mycobacterium tuberculosis (Mtb ) in 97.3% (364/374) of AFB smear-positive samples and 76.5% (13/17) among smear-negative samples, and the corresponding values for LPA test (valid results with Mtb control band) were 97.9% (366/374) and 58.8% (10/17), respectively. For detection of RR among Mtb positive molecular results, the sensitivity of Xpert MTB/RIF assay and LPA (after resolving discordant phenotypic DST results with DNA sequencing) were found to be 96% and 99%, respectively. Whereas, specificity of both test for detecting RR were found to be 99%. Conclusion We conclude that although Xpert MTB/RIF assay is comparatively superior to LPA in detecting Mtb among AFB smear-negative pulmonary TB. However, both tests are equally efficient in early diagnosis of AFB smear-positive presumptive RR-TB patients.
topic multidrug-resistant tuberculosis
complex
nontuberculous mycobacteria
mutation
url http://e-trd.org/upload/pdf/trd-2020-0171.pdf
work_keys_str_mv AT rajnarayanyadav comparativeperformanceoflineprobeassayversion2andxpertmtbrifassayforearlydiagnosisofrifampicinresistantpulmonarytuberculosis
AT binitkumarsingh comparativeperformanceoflineprobeassayversion2andxpertmtbrifassayforearlydiagnosisofrifampicinresistantpulmonarytuberculosis
AT rohinisharma comparativeperformanceoflineprobeassayversion2andxpertmtbrifassayforearlydiagnosisofrifampicinresistantpulmonarytuberculosis
AT jigyasachaubey comparativeperformanceoflineprobeassayversion2andxpertmtbrifassayforearlydiagnosisofrifampicinresistantpulmonarytuberculosis
AT sanjeevsinha comparativeperformanceoflineprobeassayversion2andxpertmtbrifassayforearlydiagnosisofrifampicinresistantpulmonarytuberculosis
AT pankajjorwal comparativeperformanceoflineprobeassayversion2andxpertmtbrifassayforearlydiagnosisofrifampicinresistantpulmonarytuberculosis
_version_ 1721338409330409472